Syncom Formulations (India) Ltd Falls to 52-Week Low Amid Continued Downtrend

Stock Price Movement and Market Context

On 2 Mar 2026, Syncom Formulations’ stock price fell by 4.62% in a single trading session, underperforming the Pharmaceuticals & Biotechnology sector by 4.03%. This decline extends a two-day losing streak during which the stock has dropped nearly 5.0%. The current price of Rs.11.36 is substantially lower than its 52-week high of Rs.23.46, representing a decline of approximately 51.6% from that peak.

The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum. This contrasts with the broader market, where the Sensex, despite a gap down opening of 2,743.46 points, recovered by 1,267.44 points to trade at 79,811.17, down 1.82% on the day. The Sensex remains below its 50-day moving average but benefits from a 50DMA positioned above the 200DMA, indicating a mixed but relatively stable market environment.

Long-Term Performance and Financial Trends

Over the past year, Syncom Formulations has delivered a negative return of 20.65%, significantly lagging behind the Sensex’s positive 9.02% gain and the BSE500’s 13.82% return. This underperformance reflects deeper issues in the company’s growth trajectory. Over the last five years, the company’s net sales have contracted at an annualised rate of 63.92%, while operating profit has declined by 50.69% annually. These figures highlight a prolonged period of shrinking revenues and profitability pressures.

Despite these declines, the company has maintained positive quarterly results for seven consecutive quarters, suggesting some stability in recent earnings. The half-yearly return on capital employed (ROCE) peaked at 22.06%, and the operating profit to net sales ratio reached a high of 18.42% in the same period. Additionally, the debtors turnover ratio stood at 5.04 times, indicating efficient receivables management.

Valuation and Shareholding Insights

Syncom Formulations currently holds a Mojo Score of 40.0 with a Mojo Grade of Sell, downgraded from Hold on 9 Feb 2026. The company’s market capitalisation grade is rated at 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector. Domestic mutual funds hold no stake in the company, which may indicate limited institutional confidence or interest at current valuations.

The stock trades at a price-to-book value of 3.2, which is a premium relative to its peers’ historical averages. Its return on equity (ROE) stands at 16.6%, suggesting a fair valuation given the company’s profitability metrics. Notably, the company’s profits have risen by 76.1% over the past year, despite the stock’s negative price performance, resulting in a low PEG ratio of 0.2. This divergence between earnings growth and share price performance highlights market scepticism or other external factors influencing investor sentiment.

Financial Structure and Risk Profile

Syncom Formulations maintains a conservative financial structure, with an average debt-to-equity ratio of just 0.05 times. This low leverage reduces financial risk and interest burden, which could be a stabilising factor amid the company’s revenue and profit fluctuations. However, the lack of significant debt has not translated into share price resilience in the current market environment.

Sector and Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Syncom Formulations has underperformed both the sector and broader market indices over the last year. While the sector has seen positive returns, the company’s stock has declined sharply, reflecting company-specific challenges rather than sector-wide issues. The Sensex’s partial recovery after a steep opening drop contrasts with the stock’s continued weakness, underscoring its relative underperformance.

Summary of Key Metrics

To summarise, Syncom Formulations (India) Ltd’s stock has reached a new 52-week low of Rs.11.36, reflecting a sustained downtrend over recent sessions. The company’s long-term sales and operating profit growth rates have been negative, while recent quarters have shown consistent positive earnings. The stock trades below all major moving averages and has underperformed the broader market and sector indices over the past year. Its financial leverage remains low, and valuation metrics indicate a premium relative to peers despite the share price decline.

These factors collectively illustrate the current market environment for Syncom Formulations, characterised by subdued investor confidence and ongoing price pressure despite some positive financial indicators.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →